Ethical Screening organised a round table discussion between chemists and life scientists, including NC3R representation, about the feasibility of screening academics’ compounds using ethical screening techniques, ways to validate ethical screening platforms and use them to discover new modulators of disease pathogenesis and to promote the refinement, reduction and replacement of animal models in pre-clinical work. Much common ground was established and a broad scope of potential areas for collaboration were identified, including advancing Dictyostelium, Xenopus and Zebra fish platforms, hit identification for epilepsy treatment and to advance understanding of mechanisms of thrombosis. Continuing work in this area over the next two years will be led by the University of Sussex focussing on establishing new programmes.

To find out more please contact us.